Investors fan the flames of Ebola fears in the market, enabling these biotech companies to profit from these fears. Ultimately these fears and some hopes of potential contracts or increased orders have been accounted for and prices have risen as a result in some of the key Ebola stocks.

Allied Healthcare Products Inc. (NASDAQ: AHPI) saw its shares rise over 44% to $3.12 from the previous close of $2.16. The company is a manufacturer of respiratory therapy and emergency medical supplies. It would appear that Allied Healthcare has gotten a piece of the Ebola pie with its emergency and respiratory equipment. Its stock has a consensus analyst price target of $4.51 and a 52-week trading range of $1.60 to $3.90.

Chimerix Inc. (NASDAQ: CMRX) saw its shares rise over 8% to $34.94 from the previous close of $32.18. Chimerix is a biopharmaceutical company that discovers and develops oral antivirals. The company recently announced that brincidofovir has been provided for potential use with patients with Ebola. Emergency Investigational New Drug Applications (EIND) were granted by the U.S. Food and Drug Administration (FDA). The company’s stock has a 52-week trading range of $12.96 to $36.45.

ALSO READ: 9 High-Yield Dividends for Risk Takers

iBio Inc. (NYSEMKT: IBIO) saw its shares rise roughly 33% to $1.84, from its previous close $1.39, Thursday on more developments in the fight against Ebola. The company announced that in collaboration with Caliber Biotherapeutics, it will help the in the government effort to ramp up production of Ebola-related drugs. iBio uses the iBioLaunch platform, which is a proprietary gene expression technology capable of producing high levels of target proteins in plants. Ultimately these proteins are used to create vaccines and can be produced quickly and efficiently. Using this technology iBio can bring its Ebola treatment to market quicker than expected. iBio’s shares have a consensus analyst price target of $3.00 and a 52-week trading range of $0.24 to $1.57.

Lakeland Industries Inc. (NASDAQ: LAKE) saw its shares rise about 3% to $24.27 from its previous close $23.60. It has been a major beneficiary of the U.S. “Ebola outbreak,” seeing its shares rise about 240% since the beginning of the scare. Lakeland primarily produces protective clothing, ranging from firefighting-suits to hazmat suits. As fears of Ebola continue to ramp up, hazmat suits will continue to be in demand. Shares of Lakeland have a consensus analyst price target of $7.35 and a 52-week trading range of $4.75 to $29.55.

Sarepta Therapeutics Inc. (NASDAQ: SRPT) saw its shares gain over 6% to $22.23 from the previous closing price of $20.91. Sarepta is a medical research and drug development company. It has also joined in on riding the Ebola wave. Sarepta’s treatment is considered one of the more promising Ebola treatments, as its tests with monkeys were shown to have a 60% to 80% success rate. Shares a consensus analyst price target of $37.94 and a 52-week trading range of $12.12 to $47.60.

Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR) saw its shares fall over 2% to $23.25 from the previous close of $23.90. Tekmira is a Canadian company that is currently developing an experimental Ebola treatment. The FDA announced in August that it would give Tekmira the go-ahead to begin treating human patients who were infected with the Ebola virus with its experimental treatment. The stock has a consensus analyst price target of $27.54 and a 52-week trading range of $7.17 to $31.48.

ALSO READ: Top Biotech Stocks Could Explode Higher After Huge Sell-Off

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.